Citius Oncology (CTOR) vs. Its Peers Head-To-Head Comparison

Citius Oncology (NASDAQ:CTOR) is one of 617 publicly-traded companies in the “MED – BIOMED/GENE” industry, but how does it compare to its competitors? We will compare Citius Oncology to similar companies based on the strength of its analyst recommendations, valuation, profitability, earnings, institutional ownership, risk and dividends.

Analyst Recommendations

This is a summary of recent recommendations for Citius Oncology and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Oncology	1	0	2	0	2.33
Citius Oncology Competitors	6644	12473	38222	1215	2.58

Citius Oncology currently has a consensus price target of $6.00, indicating a potential upside of 479.71%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 53.38%. Given Citius Oncology’s higher possible upside, equities analysts clearly believe Citius Oncology is more favorable than its competitors.

Earnings and Valuation

This table compares Citius Oncology and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Citius Oncology	N/A	-$24.76 million	-3.04
Citius Oncology Competitors	$896.91 million	-$44.22 million	10.30

Citius Oncology’s competitors have higher revenue, but lower earnings than Citius Oncology. Citius Oncology is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Citius Oncology has a beta of 2.98, meaning that its share price is 198% more volatile than the S&P 500. Comparatively, Citius Oncology’s competitors have a beta of 0.90, meaning that their average share price is 10% less volatile than the S&P 500.

Insider & Institutional Ownership

70.5% of Citius Oncology shares are held by institutional investors. Comparatively, 51.3% of shares of all “MED – BIOMED/GENE” companies are held by institutional investors. 6.7% of Citius Oncology shares are held by insiders. Comparatively, 13.4% of shares of all “MED – BIOMED/GENE” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Citius Oncology and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Citius Oncology	N/A	-65.79%	-26.15%
Citius Oncology Competitors	-906.16%	-572.54%	-29.84%

Summary

Citius Oncology beats its competitors on 8 of the 13 factors compared.

Citius Oncology Company Profile

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.